

# Azeez Farooki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9340018/publications.pdf>

Version: 2024-02-01

36  
papers

1,698  
citations

393982

19  
h-index

360668

35  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2350  
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Task Force Report: Bone Health in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-1-S-50.	2.3	245
2	Osteonecrosis of the Jaw Related to Bevacizumab. Journal of Clinical Oncology, 2008, 26, 4037-4038.	0.8	201
3	Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. Journal of Clinical Oncology, 2012, 30, 2919-2928.	0.8	188
4	NCCN Task Force Report: Bone Health in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-32.	2.3	163
5	Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy. Oncologist, 2008, 13, 911-920.	1.9	135
6	Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2433-2439.	1.8	113
7	Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates. Journal of Bone and Joint Surgery - Series A, 2011, 93, 1235-1242.	1.4	92
8	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum, 2018, 2, pky021.	1.4	92
9	Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocrine-Related Cancer, 2014, 21, R247-R259.	1.6	66
10	Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. Oncologist, 2017, 22, 438-444.	1.9	39
11	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 135-141.	0.2	37
12	Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine, 2017, 129, 159-168.	0.9	31
13	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clinical Genitourinary Cancer, 2015, 13, e305-e309.	0.9	30
14	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. Journal of Nuclear Medicine, 2021, 62, 446-454.	2.8	25
15	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leukemia Research, 2013, 37, 790-794.	0.4	24
16	Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. Endocrine, 2014, 47, 266-272.	1.1	24
17	Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Annals of the New York Academy of Sciences, 2011, 1218, 80-87.	1.8	23
18	Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 265-270.	0.7	22

#	ARTICLE	IF	CITATIONS
19	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017, 7, 32-37.	1.0	21
20	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1115-e1123.	1.8	20
21	Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1352-1357.	0.9	19
22	Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 2768-2775.	0.5	15
23	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	2.0	14
24	Anabolic Therapies for Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 2410-2411.	13.9	11
25	NCCN Bone Health Task Force: Key Recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 813-816.	2.3	10
26	Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1125-1135.	1.1	9
27	Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin: Response to Bowker et al.. <i>Diabetes Care</i> , 2006, 29, 1989-1990.	4.3	8
28	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 126-132.	2.0	6
29	Insulin Resistance and Cancer-Related Mortality. <i>Journal of Clinical Oncology</i> , 2007, 25, 1628-1629.	0.8	5
30	Denosumab and fracture risk in women with breast cancer. <i>Lancet</i> , The, 2015, 386, 2056-2057.	6.3	4
31	Maintaining Bone Health During Hormonal Therapy for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2017, 167, 357.	2.0	2
32	Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961984141.	0.3	1
33	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSISâ€”2020 UPDATE EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2020, , .	1.1	1
34	Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience. <i>HSS Journal</i> , 2021, 17, 185-191.	0.7	1
35	Risk assessment for severe hypocalcemia requiring hospitalization with denosumab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 115-115.	0.8	1
36	Impact of Hematopoietic Stem Cell Transplant (HSCT) Vitamin D Algorithm on Vitamin D Levels of HSCT Patientsâ€”Part II. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S113-S114.	2.0	0